NancyUan-TsinLinMD

Breast Cancer

Associate Professor of Medicine, Harvard Medical School; Associate Chief, Division of Breast Oncology Center, Dana-Farber Cancer Institute

Join to view full profile

Dr. Lin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Lin's full profile

Already have an account?

Office
450 Brookline Avenue
Dana-Farber Cancer Institute
Boston, MA 02215
Phone+1 617-632-3800

Fax+1 617-632-1930
Is this information wrong?

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2002 - 2005
Brigham and Women's HospitalResidency, Internal Medicine, 1999 - 2002
Harvard Medical SchoolClass of 1999

Certifications & Licensure

FL State Medical License 2022 - Present
MA State Medical License 2002 - 2025
VT State Medical License 2023 - 2024
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer Start of enrollment: 2007 May 14
Active, not recruiting
Phase 2
Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer Start of enrollment: 2007 Apr 01
Completed
Phase 1
ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases Start of enrollment: 2007 Jul 01
Terminated
Phase 2
Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU Start of enrollment: 2007 Nov 01
Terminated
Phase 3
Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases Start of enrollment: 2009 Nov 01
Completed
Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer Start of enrollment: 2011 Aug 01
Completed
Phase 1, Phase 2
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases Start of enrollment: 2011 Oct 01
Completed
Phase 2
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer Start of enrollment: 2012 May 01
Active, not recruiting
Phase 2
A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 2
BKM120 For Triple Negative Breast Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 2
ARRY-380 + Trastuzuamab for Breast w/ Brain Mets Start of enrollment: 2013 Aug 01
Completed
Phase 1
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer Start of enrollment: 2014 May 01
Terminated
Phase 1, Phase 2
Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer Start of enrollment: 2016 Apr 07
Completed
Phase 2
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC Start of enrollment: 2018 May 21
Active, not recruiting
Phase 2
Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer Start of enrollment: 2019 Sep 16
Suspended
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancer.
Stefania Morganti, Qingchun Jin, Julie Vincuilla, Ryan Buehler, Sean Ryan, Samantha Stokes, Tonia Parker, Elizabeth A Mittendorf, Tari A King, Anna Weiss, Ann H Partri...> ;NPJ Breast Cancer. 2024 Apr 16
Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer.
Julieta Leone, Carlos T Vallejo, Olga Martínez-Sáez, Nabihah Tayob, Paolo Tarantino, Rachel A Freedman, Adrienne G Waks, Ana Garrido-Castro, Filipa Lynce, Nancy U Lin,...> ;NPJ Breast Cancer. 2024 Apr 4
Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trial.
Jorge Gómez Tejeda Zañudo, Romualdo Barroso-Sousa, Esha Jain, Qingchun Jin, Tianyu Li, Jorge E Buendia-Buendia, Alyssa Pereslete, Daniel L Abravanel, Arlindo R Ferreir...> ;Nature Communications. 2024 Mar 19
Survival analysis of patients with brain metastases at initial breast cancer diagnosis over the last decade.
Jorge Avila, Julieta Leone, Carlos T Vallejo, Nancy U Lin, José P Leone> ;Breast Cancer Research and Treatment. 2024 Mar 7
Mortality Risks Over 20 Years in Men With Stage I to III Hormone Receptor-Positive Breast Cancer.
Julieta Leone, Michael J Hassett, Rachel A Freedman, Sara M Tolaney, Noah Graham, Nabihah Tayob, Carlos T Vallejo, Eric P Winer, Nancy U Lin, José P Leone> ;JAMA Oncology. 2024 Apr 1
Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer.
Ajari, O., Graham, N., Vincuilla, J., Parker, T., Hughes, M., Tayob, N., Morganti, S., Curigliano, G., Tarantino, P., Garrido-Castro, A., King, T., Mittendorf, E., Lin...> ;European Journal of Cancer. 2024 Apr 1
Impact of personalized diabetes care on distress and treatment satisfaction in people with breast cancer.
Harrod, J., Buckley, L., Cromwell, G., Fowler, K., Hughes, M., Cheung, Y., Lin, N., Tolaney, S., Min, L., McDonnell, M.> ;Diabetic Medicine. 2024 Apr 1
From Serendipity to Intention: Development of Brain-Penetrant PARP1-Selective Inhibitors.
Filipa Lynce, Nancy U Lin> ;Clinical Cancer Research. 2024 Apr 1
ASO Visual Abstract: Long-Term Patient-Reported Arm Symptoms in Breast Cancer Survivors.
Lagendijk, M., Grossmith, S., Hughes, M., Eliassen, A., Laws, A., Lin, N., Mittendorf, E., King, T., Dominici, L.> ;Annals of Surgical Oncology. 2024 Apr 1
Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast Cancer.
Morganti, S., Gibson, C., Jin, Q., Santos, K., Patel, A., Wilson, A., Merrill, M., Vincuilla, J., Stokes, S., Lipsyc-Sharf, M., Parker, T., King, T., Mittendorf, E., C...> ;Journal of Clinical Oncology. 2024 Jan 8
Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer.
Guerriero, J., Lin, J., Pastorello, R., Du, Z., Chen, Y., Townsend, M., Shimada, K., Hughes, M., Ren, S., Tayob, N., Zheng, K., Mei, S., Patterson, A., Taneja, K., Met...> ;NPJ Breast Cancer. 2024 Jan 2
HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancer.
Xia, D., Kuo, F., Hughes, M., Lindeman, N., Manning, D., Files, J., Strauss, S., Kirkner, G., Mohammed-Abreu, A., Winer, E., Tolaney, S., Lin, N., Dillon, D.> ;American Journal of Clinical Pathology. 2023 Dec 16
Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer.
Tarantino, P., Gupta, H., Hughes, M., Files, J., Strauss, S., Kirkner, G., Feeney, A., Li, Y., Garrido-Castro, A., Barroso-Sousa, R., Bychkovsky, B., DiLascio, S., Sho...> ;Nature Communications. 2023 Dec 14
Long-Term Patient-Reported Arm Symptoms in Breast Cancer Survivors.
Lagendijk, M., Grossmith, S., Hughes, M., Eliassen, A., Laws, A., Lin, N., Mittendorf, E., King, T., Dominici, L.> ;Annals of Surgical Oncology. 2024 Mar 1
Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance.
Kim, A., Lou, K., Giobbie-Hurder, A., Chang, K., Gidwani, M., Hoebel, K., Patel, J., Cleveland, M., Singh, P., Bridge, C., Ahmed, S., Bearce, B., Liu, W., Fuster-Garci...> ;Neuro-Oncology. 2023 Dec 9
2 citations
Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression.
Jun Nishida, Simona Cristea, Sudheshna Bodapati, Julieann Puleo, Gali Bai, Ashka Patel, Melissa Hughes, Craig Snow, Virginia Borges, Kathryn J Ruddy, Laura C Collins, ...> ;Proceedings of the National Academy of Sciences of the United States of America. 2023 Dec 5
Author Correction: Liquid biopsy epigenomic profiling for cancer subtyping.
Sylvan C Baca, Ji-Heui Seo, Matthew P Davidsohn, Brad Fortunato, Karl Semaan, Shahabbedin Sotudian, Gitanjali Lakshminarayanan, Miklos Diossy, Xintao Qiu, Talal El Zar...> ;Nature Medicine. 2024 Mar 1
2 citations
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer.
Tarantino, P., Gupta, H., Hughes, M., Files, J., Strauss, S., Kirkner, G., Feeney, A., Li, Y., Garrido-Castro, A., Barroso-Sousa, R., Bychkovsky, B., DiLascio, S., Sho...> ;Nature Communications. 2023 Nov 18
Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data.
Nancy U Lin, Priya Kumthekar, Solmaz Sahebjam, Nuhad Ibrahim, Anita Fung, Anna Cheng, Alan Nicholas, Jesse Sussell, Mark Pegram> ;NPJ Breast Cancer. 2023 Nov 17
4 citations
Liquid biopsy epigenomic profiling for cancer subtyping.
Sylvan C Baca, Ji-Heui Seo, Matthew P Davidsohn, Brad Fortunato, Karl Semaan, Shahabbedin Sotudian, Gitanjali Lakshminarayanan, Miklos Diossy, Xintao Qiu, Talal El Zar...> ;Nature Medicine. 2023 Nov 1
Keeping It in the Family: HER3 as a Target in Brain Metastases.
Sheheryar Kabraji, Nancy U Lin> ;Clinical Cancer Research. 2023 Aug 15
5 citations
Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results.
Priscilla K Brastianos, Albert E Kim, Anita Giobbie-Hurder, Eudocia Q Lee, Nancy U Lin, Beth Overmoyer, Patrick Y Wen, Lakshmi Nayak, Justine V Cohen, Jorg Dietrich, A...> ;Nature Medicine. 2023 Jul 1
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer.
Ana C Garrido-Castro, Meredith M Regan, Samuel M Niman, Faina Nakhlis, Claire Remolano, Jennifer M Rosenbluth, Caroline Block, Laura E Warren, Jennifer R Bellon, Eren ...> ;NPJ Breast Cancer. 2023 Jun 2
Estimating mortality in women with triple-negative breast cancer: The 'ESTIMATE triple-negative' tool.
José P Leone, Noah Graham, Julieta Leone, Sara M Tolaney, Bernardo A Leone, Rachel A Freedman, Michael J Hassett, Carlos T Vallejo, Eric P Winer, Nancy U Lin, Nabihah ...> ;European Journal of Cancer. 2023 Aug 1
1 citations
Tucatinib Plus Trastuzumab and Capecitabine for ERBB2 (HER2)-Positive Metastatic Breast Cancer With Brain Metastases-Reply.
Nancy U Lin> ;JAMA Oncology. 2023 Jul 1
Join now to see all

Journal Articles

Attitudes of Patients with Metastatic Cancer Towards Research Biopsies
Nancy Lin, MD, Asia‐Pacific Journal of Clinical Oncology

Press Mentions

FDA Approves AstraZeneca, Daiichi Drug in Breast Cancer FirstAugust 5th, 2022
‘Dramatic’ Study Results for AstraZeneca, Daiichi Drug Suggest New Way to Treat Aggressive Breast CancerJune 5th, 2022
‘Dramatic’ Study Results for AstraZeneca, Daiichi Drug Suggests New Way to Treat Aggressive Breast CancerJune 5th, 2022
Join now to see all